Title : Revolution of transdermal patches : A novel drug delivery system
Abstract:
As an alternative to traditional needle injections, a number of non-invasive administrations have lately surfaced. The least unattractive approach among them is a transdermal drug delivery system (TDDS), which has a low rejection rate, excellent ease of administration, and outstanding patient convenience and persistence. Additionally, elderly patients need specific attention when it comes to drug delivery, drug interactions, and drug adherence. Patients with chronic neurological illnesses, in particular, may require numerous drug administrations throughout the day to maintain stable plasma medication levels, which raises the risk of non-compliance. In order to establish a constant rate of drug distribution, numerous attempts have been undertaken to design pharmacological formulations. However, the physicochemical characteristics of the skin result in a number of challenges and limitations for transdermal distribution, and several studies have been done to address these bottlenecks. In this review, we present the various types of TDDS (Transdermal Drug delivery system) approaches that are now available and critically examine the benefits and drawbacks, characterization techniques, and potential of each method. The high efficiency of TDDS has been demonstrated by advancements in research on these alternative methodologies, and it is anticipated that TDDS will find use in a variety of industries.
Audience Take Away Notes:
- The development of TDDS technology is widely acknowledged as the development of a mass delivery methodology, making it the preferred drug injection modality for transdermal delivery across the spectrum of skin types while avoiding first-pass metabolism and other sensitivities connected to various alternative drug administration routes.
- Through TDDS, drugs are typically consistently and securely administered, and they remain secure and biochemically stable up until they reach the target region. Drugs may be distributed uniformly at predetermined and controlled rates with TDDS since it is noninvasive, nonallergenic, and has a predetermined duration and dose delivery technique.
- The bioavailability of medications with low absorption is being improved by numerous new and old formulations through simple administration routes that enable big dosages to be given over an extended period of time. Because it may enhance drug delivery through topical channels, the TDDS technology is expanding quickly in the pharmaceutical industry and has been successful in gaining critical value in the market for biomedical applications.
- Because transdermal administration delivers prolonged therapeutic plasma levels of medicines, is easy to use, and may lessen systemic adverse effects, it is the optimal therapeutic method for chronic neurological illnesses in elderly persons.
- Several transdermal delivery systems are now being researched for the treatment of neuropathic pain, Parkinson's disease, and Alzheimer's disease.
- The US Food and Drug Administration (FDA) has received multiple reports of "adhesional failure" for transdermal drug delivery devices through the Drug Quality Reporting System (DQRS). It is expected that in transdermal patches the adhesive will maintain a bond with the skin, once the release liner has been removed and deliver therapeutic action to the skin without causing any kind of skin irritation
- In this presentation, we will also focus is primarily on the utilization of adhesives in the fabrication of dermal patches, tests to determine the efficacy of adhesives, and possible adhesion failures of transdermal patches.
